Swisscom Ventures and ZKB invest in Scailyte Startupticker.ch | The Swiss Startup News channel
Summary
Scailyte, a Luzern based startup specializing in single-cell technologies for precision medicine and early detection of complex diseases, has raised CHF 2.75M in seed funding. Scailyte develops artificial intelligence (AI) based software for best-in-class analysis of complex single-cell data to enhance biomedical research, pharmaceutical discovery and precision diagnostics. The raised capital will be used to enhance the market entry and to speed up further development of ScaiVision, allowing it to be more accessible and attractive to a wider range of customers. “The future of healthcare is about detecting and understanding valuable information hidden in complex data patterns,” says Peter Nestorov, CEO of Scailyte. “Hemex has supported the development of several innovative therapies and immediately recognized the potential of Scailyte’s technology to unlock «big data» in order to find more precise, personalized cures and even detect diseases before they manifest clinically in patients.